Cancerous tumours of the eye

Last medical review:

A cancerous tumour of the eye can grow into nearby tissue and destroy it. The cancer can also spread (metastasize) to other parts of the body. Cancerous tumours are also called malignant tumours. Cancerous tumours of the eye are rare.

Melanoma of the eye

Melanoma of the eye is the most common type of eye cancer in adults. It develops from cells called melanocytes. Melanocytes make melanin, the substance that gives colour to the eyes, skin and hair.

Melanoma of the eye most often starts in the eyeball. If it starts in melanocytes in the uvea, it is called uveal melanoma. If it starts in melanocytes in the conjunctiva, it is called conjunctival melanoma. Both uveal melanoma and conjunctival melanoma are types of intraocular melanoma. (Intraocular means “within the eyeball.”) Uveal melanoma is much more common than conjunctival melanoma.

Melanoma of the eye can sometimes start in melanocytes in the orbit, which is part of the eye socket. This is called orbital melanoma.

When melanoma starts in the eyelid, it is considered melanoma of the skin.

Uveal melanoma

Uveal melanoma (a type of intraocular melanoma) is the most common type of cancerous tumour of the eye in adults. Uveal melanomas make up more than 80% of all cancerous tumours of the eye.

Uveal melanomas are usually grouped by what part of the eye the tumour starts in.

Anterior uveal melanoma begins in the iris at the front of the eye. These tumours are usually slower growing and less likely to spread (metastasize).

Posterior uveal melanoma begins in the choroid or ciliary body. These structures are behind the front part of the eye. Because they can’t be seen, posterior uveal melanomas are typically found at a more advanced stage than anterior uveal melanomas. These tumours are also more likely to metastasize. Most of the time, uveal melanoma starts in the choroid.

Using a system called modified Callendar classification, posterior uveal melanoma can be classified by the appearance of the melanocytes in the tumour:

  • spindle cell melanoma – 90% or more of the cells are spindle cells (including spindle A cells and spindle B cells), which are long and thin
  • epithelioid melanoma – 90% or more of the cells are epithelioid cells, which are round
  • mixed-cell type melanoma – made up of a mixture of spindle and epithelioid cells

Lymphoma of the eye

Lymphoma of the eye is the second most common type of eye cancer. It begins in lymphocytes of the eye. A lymphocyte is a type of white blood cell that fights viruses, bacteria, foreign substances or abnormal cells (including cancer cells). In most cases, lymphoma of the eye is a type of non-Hodgkin lymphoma called diffuse large B-cell lymphoma (DLBCL).

Lymphoma of the eye can be grouped by the part of the eye that the cancer started in.

Orbital adnexal lymphoma begins in the eye socket or adnexal structures, including the conjunctiva, eyelid and tear (lacrimal) gland. It is the most common cancer of the eye socket and adnexal structures.

Intraocular lymphoma begins in the vitreous humour, uvea, retina or optic nerve. It is sometimes called ocular lymphoma or vitreoretinal lymphoma (VRL). Less than 1% of cases of eye cancer are intraocular lymphoma.

Squamous cell carcinoma of the eye

Squamous cell carcinoma (SCC) of the eye starts in squamous cells of the conjunctiva. Squamous cells are flat, thin cells that form the surface or lining of many parts of the body. This type of eye cancer is often called conjunctival SCC or SCC of the conjunctiva. SCC develops from conjunctival intraepithelial neoplasia (CIN) that has grown into the connective tissue layer of the conjunctiva.

SCC of the eye can be classified by the appearance of the cancer cells in the tumour. The cancer cells can be spindle (long and thin) or epithelioid (round).

Squamous cell carcinoma can also affect the eyelid. When this happens, it is considered to be a type of non-melanoma skin cancer.

Retinoblastoma

Retinoblastoma is the most common eye cancer in children. It rarely occurs in adults.

Find out more about retinoblastoma.

Rare tumours of the eye

The following cancerous tumours of the eye are rare:

Basal cell carcinoma (BCC) is a type of non-melanoma skin cancer. It usually starts in the eyelid and is the most common type of cancer of the eyelid.

Intraocular medulloepithelioma develops in the ciliary body. It most often affects children.

Orbital rhabdomyosarcoma is a type of soft tissue sarcoma that starts in the eye socket. It can start in the muscles that move the eye and it most often affects children. Find out more about rhabdomyosarcoma.

Sebaceous carcinoma is a type of cancer that develops in the oil glands (sebaceous glands) of the skin. It most often occurs on the upper eyelid close to the eyelash line.

 

Expert review and references

  • Tina Felfeli, MD
  • American Cancer Society. What is Eye Cancer. 2023. https://www.cancer.org/.
  • Armstrong BK, Vajdic CM, Cust AE. Melanoma. Thun MJ, Linet MS, Cerhan JR, Haiman CA Schottenfeld D, eds.. Schottenfeld and Fraumeni Cancer Epidemiology and Prevention. 4th ed. New York, NY: Oxford University Press; 2018: Kindle version, [chapter 57] https://read.amazon.ca/?asin=B0777JYQQC&language=en-CA.
  • Biswas J, Singh Sodhi PK, Weng Cy, Palestine A, Gonzales J, Tsui E, et al.. Intraocular melanoma. EyeWiki. American Academy of Opthalmology; 2024. https://eyewiki.aao.org/Main_Page.
  • Boyd K. What is eye lymphoma?. Eye Diseases and Topics, A-Z. American Academy of Opthalmology; 2023. https://www.aao.org/eye-health/a-z.
  • Cancer Research UK. What is Eye Cancer. 2021. https://www.cancerresearchuk.org/.
  • Choudhary MM, Singh AD. Ophthalmic cancers. Raghavan D, Ahluwalia MS, Blanke CD, et al, eds.. Textbook of Uncommon Cancers. 5th ed. Hoboken, NJ: Wiley Blackwell; 2017: Kindle version chapter 68 https://read.amazon.ca/?asin=B06XKD44V3&_encoding=UTF8&ref=dbs_p_ebk_r00_pbcb_rnvc00.
  • Cleveland Clinic. Conjunctival Melanoma. 2023. https://my.clevelandclinic.org/.
  • Columbia University. Eye Lymphoma. New York, NY: https://www.columbiadoctors.org/. March 20, 2024.
  • He L, Zhang J, Chen X, Wei R. Epidemiology and survival outcomes of patients with primary intraocular lymphoma: a population based analysis. BMC Ophthalmology. 2022: 22:486.
  • Isidro MA. Medscape Reference: Retinoblastoma Epidemiology. 2019. https://www.medscape.com/oncology.
  • Kwon M, Lee JS, Lee C, Yoon DH, Sa HS. Prognostic factors for relapse and survival among patients with ocular adnexal lymphoma: validation of the eigth edition of the American Joint Committee on Cancer (AJCC) TNM classification. British Journal of Ophthalmology. 2021: 105(2): 279–284.
  • PDQ Adult Treatment Editorial Board. Intraocular (Uveal) Melanoma Treatment (PDQ®) – Health Professional Version. Bethesda, MD: National Institutes of Health; 2023. https://www.cancer.gov/.
  • Porter D. What is ocular melanoma?. Eye Diseases and Topics, A-Z. American Academy of Opthalmology; 2022. https://www.aao.org/eye-health/a-z.
  • Roque MR. Medscape Reference: Ocular Lymphoma. 2022. https://www.medscape.com/oncology.
  • Seladi-Schulman J. Understanding Eye Cancer: Types, Symptoms, Treatment. Healthline; 2023. https://www.healthline.com/.
  • Stålhamman G, Gill TY. Digital morphometry and cluster analysis identifies four types of melanocytes during uveal melanoma progression. Communications Medicine. 2023: 3:60.

Your trusted source for accurate cancer information

With just $5 from readers like you, we can continue to provide the highest quality cancer information for over 100 types of cancer.

We’re here to ensure easy access to accurate cancer information for you and the millions of people who visit this website every year. But we can’t do it alone.

If everyone reading this gave just $5, we could achieve our goal this month to fund reliable cancer information, compassionate support services and the most promising research. Please give today because every contribution counts. Thank you.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2025 Canadian Cancer Society